[TECHNOLOGY OPPORTUNITY 1998-003]

<< Back to Life Sciences

Monoclonal Antibodies to Baculovirus Proteins
1998-003

The Technology:
A suite of monoclonal antibodies directed to baculovirus proteins was produced in mouse hybridoma cell lines, isolated and characterized. The antibodies bind specifically to structural proteins of the baculovirus Autographa californica nuclear polyhedrosis virus (AcMNPV). Of special interest are monoclonals AcV1 and AcV5 which specifically bind to the principal viral envelope glycoprotein, gp64, of the budded virus (BV) phenotype. Both AcV1 and AcV5 are highly specific for the antigen and can be employed in standard immunological assays and purification protocols, e.g., western blotting, immunoprecipitation and immunoadsorption procedures. In addition, AcV1 completely and specifically neutralizes the infectivity of the budded virus phenotype.

Commercial Status:
PARTEQ is seeking licensees for this technology.

Contact:
Perry M. Kim, PhD
Manager, Commercial Development
PARTEQ Innovations
Biosciences Complex
Queen's University
Kingston, ON K7L 3N6
P: 613. 533. 2342 F:613. 533. 6853
pkim@parteqinnovations.com